Clinical Trials
SeaStar Medical Advances Kidney Injury Treatment with Innovative Pediatric Therapy
SeaStar Medical's QUELIMMUNE therapy offers promising treatment for pediatric acute kidney injury, with FDA approval and early hospital adoption signaling potential breakthrough in a critical healthcare challenge.
Oragenics to Discuss Promising Concussion Treatment in Upcoming Webinar
Biotechnology company Oragenics will host a management webinar to highlight its lead intranasal therapy ONP-002, currently in Phase IIa trials for mild traumatic brain injury, potentially addressing an unmet medical need in concussion treatment.
Quantum BioPharma Advances Multiple Sclerosis Drug Candidate Through Critical Toxicity Studies
Quantum BioPharma has completed key 90-day toxicity studies for its multiple sclerosis drug candidate Lucid-21-302, positioning the company to file an Investigational New Drug application with the FDA and potentially develop a first-in-class MS therapy.
NRx Pharmaceuticals Set to Release Q1 2025 Financial Results and Provide Corporate Update
NRx Pharmaceuticals will disclose its first quarter 2025 financial performance and host a conference call, offering insights into its ongoing clinical-stage therapeutics development for central nervous system disorders.
Highland Park Dentist Offers Revolutionary Self-Administered Pain Relief Technique for Migraines and Headaches
Dr. Ira Shapira teaches patients and medical professionals a self-administered technique for Sphenopalatine Ganglion (SPG) Blocks, offering rapid pain relief for migraines, cluster headaches, and other autonomic cephalgias using a minimally invasive method.
Clene Inc. Advances CNM-Au8 Toward Potential Accelerated Approval for ALS
Clene Inc. reports promising progress on its CNM-Au8 therapy for ALS, with plans to submit a New Drug Application under the FDA's Accelerated Approval pathway, supported by significant survival data and reduced expenses.
Clene Inc. Advances Promising Therapy for ALS, Targets Accelerated FDA Approval
Clene Inc. reports significant progress on CNM-Au8, a potential breakthrough therapy for amyotrophic lateral sclerosis (ALS), with plans to submit a New Drug Application under the FDA's Accelerated Approval pathway in Q4 2025. New data demonstrates improved patient survival and neurological repair.
TransCode Therapeutics Advances RNA Cancer Therapy, Reaches Milestone in Phase 1a Trial
TransCode Therapeutics has successfully dosed 15 patients in its Phase 1a trial for RNA-based cancer therapeutic TTX-MC138, with early data showing promising target engagement and no significant toxicities.
NanoViricides Secures Ethics Approval for Mpox Phase II Trial in Democratic Republic of Congo
NanoViricides has received ethical clearance to conduct a Phase II clinical trial for NV-387, a broad-spectrum antiviral drug targeting Mpox, signaling potential progress in viral disease treatment strategies.
GeoVax Reveals Promising Dual-Action Vaccine with Potential COVID-19 and Mpox Protection
A novel vaccine candidate, GEO-CM04S1, demonstrates robust immunogenicity against both COVID-19 and Mpox in immunocompromised and healthy populations, offering potential breakthrough in infectious disease prevention.
Clene Inc. to Present at D. Boral Capital Global Conference in New York
Clene Inc., a late clinical-stage biopharmaceutical company developing neurological disease treatments, will participate in the D. Boral Capital Inaugural Global Conference, offering investors an opportunity to learn about its innovative research and potential therapeutics.
Soligenix CEO Highlights Rare Disease Therapeutics and Public Health Solutions Strategy
Soligenix's CEO discusses the company's two-pronged business model focused on rare disease treatments and public health solutions, emphasizing significant government funding and promising clinical trial developments.
Kairos Pharma to Showcase Oncology Research at D. Boral Capital Global Conference
Kairos Pharma will participate in the D. Boral Capital Inaugural Global Conference, offering investors insights into its innovative cancer therapeutic research, focusing on overcoming drug resistance with its lead candidate ENV105.
Soligenix's HyBryte Shows Promising Results in CTCL Treatment, Offering New Hope for Rare Skin Cancer Patients
Biotechnology company Soligenix has reported impressive interim results for HyBryte, a novel topical treatment for cutaneous T-cell lymphoma (CTCL), demonstrating a 75% response rate and potential to address a significant unmet medical need.
Aditxt Advances ADI-100 Therapeutic Development with Leadership Update
Aditxt Inc. continues to develop innovative immune-modulating therapies through its ADI-100 therapeutic candidate, highlighting ongoing progress in its health innovation platform. The company's strategic approach involves collaborative research and potential expansion into multiple health domains.
GeoVax Advances COVID-19, Cancer, and Biosecurity Vaccine Platforms Despite BARDA Contract Setback
GeoVax Labs reports significant progress across multiple vaccine development programs, including a multi-antigen COVID-19 vaccine for immunocompromised patients, an oncology treatment for head and neck cancer, and a Mpox/smallpox vaccine addressing global biosecurity needs.
Soligenix Advances Treatment for Rare Skin Cancer with HyBryte™ Therapy
Soligenix's HyBryte™ therapy shows promise in treating early-stage cutaneous T-cell lymphoma, potentially addressing a significant gap in rare disease treatments within a rapidly growing global market.
TransCode Therapeutics Advances RNA Cancer Therapy in Phase 1a Trial, Shows Promising Early Results
TransCode Therapeutics reports encouraging progress in its Phase 1a trial of TTX-MC138, an RNA-based cancer therapy targeting microRNA-10b, with initial data suggesting potential effectiveness in treating metastatic tumors.
Scinai Immunotherapeutics to Discuss Potential Breakthrough Treatment for Rare Skin Disorders
Scinai Immunotherapeutics will host a webinar to explore the therapeutic potential of PC111, a novel monoclonal antibody targeting rare skin conditions like Pemphigus Vulgaris and SJS/TEN, following its recent acquisition of Pincell.
Monogram Technologies Receives Indian Regulatory Approval for Robotic Knee Surgery Clinical Trial
Monogram Technologies has secured regulatory approval to conduct a multi-center clinical trial in India for its mBôs TKA robotic total knee replacement system, marking a significant step toward potential commercial launch and advancement in orthopedic surgical technology.
Soligenix Advances HyBryte Therapy for Cutaneous T-Cell Lymphoma Treatment
Soligenix is progressing its phase 3 clinical trial for HyBryte, a novel photodynamic therapy targeting early-stage cutaneous T-cell lymphoma, with potential to provide a noninvasive and precise treatment option for patients.
GeoVax Presents Promising Clinical Data for Gedeptin® Gene Therapy in Head and Neck Cancer Treatment
GeoVax Labs revealed clinical trial results for Gedeptin®, a novel gene-directed prodrug therapy showing potential in treating advanced head and neck cancers with minimal side effects and stability in patient outcomes.
Neutra Life Sciences Expands Clinical Research Network with Four New Specialized Medical Sites
Neutra Corp's subsidiary, Neutra Life Sciences, has rapidly expanded its clinical research capabilities by establishing joint venture partnerships with four specialized medical practices across diverse healthcare specialties. The strategic growth positions the company to support broader clinical research needs and accelerate medical innovation.
Annovis Bio Bolsters Neurodegenerative Research with Key Biostatistics Appointment
Annovis Bio strengthens its scientific team by appointing Hui Liu as Director of Biostatistics, enhancing its capabilities in clinical trial design and data analysis for neurodegenerative disease research.
AHA Awards $1M to Study Cardiovascular Benefits of GLP-1 Medications Across Diverse Populations
The American Heart Association is funding seven research projects to investigate how GLP-1 medications impact cardiovascular health in different patient groups, with the goal of identifying who benefits most from these treatments and understanding variations in therapeutic response.
BriaCell Therapeutics Raises $13.8 Million in Public Offering to Advance Cancer Immunotherapy Research
BriaCell Therapeutics has completed a public offering of 3,066,666 units, generating approximately $13.8 million to support its clinical-stage cancer immunotherapy development efforts. The funding will help the company advance its research and corporate objectives.
Kairos Pharma to Present Promising Cancer Treatment Data at 2025 ASCO Meeting
Kairos Pharma will showcase new research on KROS 101, a small molecule GITR ligand agonist, potentially offering insights into innovative cancer treatment approaches at the prestigious ASCO Annual Meeting.
Soligenix Advances Promising Skin Cancer Treatment with 75% Response Rate
Soligenix's HyBryte™ therapy shows significant potential in treating cutaneous T-cell lymphoma, with a 75% response rate in a federally supported clinical trial. The innovative, light-activated treatment could offer new hope for patients with this rare form of skin cancer.
NeuroSense Advances Promising ALS Treatment with Potential Global Partnership
Biotech company NeuroSense Therapeutics is in advanced discussions for a pharmaceutical partnership that could accelerate its innovative ALS treatment PrimeC, demonstrating significant survival improvements in clinical trials.
GeoVax Reveals Promising Multi-Antigen COVID-19 Vaccine with Strong Immunocompromised Patient Response
GeoVax's experimental COVID-19 vaccine GEO-CM04S1 demonstrates exceptional immune responses across diverse populations, particularly in immunocompromised patients, potentially offering a more robust alternative to existing vaccines.